Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
This combination of effects is believed to result in more comprehensive metabolic benefits
Current evidence from large-scale clinical trials and regulatory surveillance does not establish a causal link between GLP-1 receptor agonists and increased risk of venous thromboembolism (deep vein thrombosis or pulmonary embolism)
Wegovy lowered the risk of major cardiovascular events by 20% in a clinical trial that included over 17,000 adults ages 45 and older who have a history of cardiovascular disease and are overweight or obese, according to the Novo Nordisk-funded study
Its long half-life allows for once-daily dosing and may ease transitions if doses are occasionally missed
Int J Mol Sci (2015) 16(9):20195211
The patent was issued in 2019 and would provide market protection until 2033, according to the FDAs Orange Book, a listing of patents for approved drugs
US$ 24.58
US$ 27.83
US$ 25.00
US$ 24.23
